Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: cgraham who wrote (789)	9/14/1998 3:58:00 PM
From: Anthony Wong	Respond to of 1722

From a Bloomberg PFE article update: 'It will be incredibly well received and sought after by patients,'' predicted Leonard Yaffe, an analyst at NationsBanc Montgomery Securities who has a ''buy'' on Pfizer and said it's his favorite drug stock. At a recent European medical meeting on impotence, there was ''lots of talk about Viagra,'' he said. Europe is the third-largest market for Pfizer, behind the U.S. and Japan. Yaffe said he expects Viagra will have sales of between $200 million and $300 million in the first three months on the European market. news.com